Tokyo Tape
Sign in
← Otsuka Holdings

Half-year report · HY

4578.TEDINET S100YTLB
Period2026-01-01 → 2026-06-30
Filed2026-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.33T2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥2.47T2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.18T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income¥278.5bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income¥242.1bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax¥285.4bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax¥468.0bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥226.3bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥215.6bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥363.1bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥173.5bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥218.5bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income¥175.9bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥4.40Tat 2026-06-30Cons.Assets IFRS
Total assets¥4.20Tat 2025-12-31Cons.Assets IFRS
Total assets¥3.79Tat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.09Tat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥1.10Tat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥3.31Tat 2026-06-30Cons.Equity IFRS
Net assets / equity¥3.10Tat 2025-12-31Cons.Equity IFRS
Net assets / equity¥2.79Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥2.78Tat 2024-12-31vCons.Equity IFRS
Equity (owners)¥3.24Tat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥3.03Tat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.72Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥469.5bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥534.6bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥411.1bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥426.2bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥217.1bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥403.6bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥212.7bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥173.0bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥161.6bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥130.9bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥114.3bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥137.3bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥85.4bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥409.072026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥685.062025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥326.122025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
Equity ratio73.7%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.3%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.8%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2026-01-01 → 2026-06-30¥65.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2026-01-01 → 2026-06-30¥63.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2026-01-01 → 2026-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2026-01-01 → 2026-06-30¥6.2bn
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥28.7bn
Consumer Productsreportable segmentrevenue2026-01-01 → 2026-06-30¥17.5bn
Consumer Productsreportable segmentrevenue external2026-01-01 → 2026-06-30¥17.4bn
Consumer Productsreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥15m
Consumer Productsreportable segmentsegment profit2026-01-01 → 2026-06-30¥13.8bn
Nutraceuticalsreportable segmentrevenue2026-01-01 → 2026-06-30¥300.1bn
Nutraceuticalsreportable segmentrevenue external2026-01-01 → 2026-06-30¥300.1bn
Nutraceuticalsreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥16m
Nutraceuticalsreportable segmentsegment profit2026-01-01 → 2026-06-30¥36.8bn
Pharmaceuticalsreportable segmentrevenue2026-01-01 → 2026-06-30¥951.6bn
Pharmaceuticalsreportable segmentrevenue external2026-01-01 → 2026-06-30¥951.6bn
Pharmaceuticalsreportable segmentsegment profit2026-01-01 → 2026-06-30¥250.4bn
—segment totalrevenue2026-01-01 → 2026-06-30¥1.33T
—segment totalrevenue external2026-01-01 → 2026-06-30¥1.33T
—segment totalrevenue intersegment2026-01-01 → 2026-06-30¥1.8bn
—segment totalsegment profit2026-01-01 → 2026-06-30¥307.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥56.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥55.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30¥5.0bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥27.8bn
Consumer Productsreportable segmentrevenue2025-01-01 → 2025-06-30¥15.8bn
Consumer Productsreportable segmentrevenue external2025-01-01 → 2025-06-30¥15.8bn
Consumer Productsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥9m
Consumer Productsreportable segmentsegment profit2025-01-01 → 2025-06-30¥12.9bn
Nutraceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥276.1bn
Nutraceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥276.0bn
Nutraceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥19m
Nutraceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥36.7bn
Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥833.8bn
Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥833.8bn
Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥215.4bn
—segment totalrevenue2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue external2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥1.7bn
—segment totalsegment profit2025-01-01 → 2025-06-30¥269.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 797
ItemContextValueUnit
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E21183-000PharmaceuticalsReportableSegmentMember215352000000JPY
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E21183-000NutraceuticalsReportableSegmentMember36681000000JPY
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E21183-000ConsumerProductsReportableSegmentMember12861000000JPY
Operating profit loss IFRSPrior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember5010000000JPY
Operating profit loss IFRSPrior1InterimDuration_ReportableSegmentsMember269905000000JPY
Operating profit loss IFRSPrior1InterimDuration_ReconcilingItemsMember-27786000000JPY
Operating profit loss IFRSPrior1InterimDuration242118000000JPY
Revenue from external customers IFRSInterimDuration_jpcrp040300-ssr_E21183-000PharmaceuticalsReportableSegmentMember951614000000JPY
Revenue from external customers IFRSInterimDuration_jpcrp040300-ssr_E21183-000NutraceuticalsReportableSegmentMember300129000000JPY
Revenue from external customers IFRSInterimDuration_jpcrp040300-ssr_E21183-000ConsumerProductsReportableSegmentMember17436000000JPY
Revenue from external customers IFRSInterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember63210000000JPY
Revenue from external customers IFRSInterimDuration_ReportableSegmentsMember1332390000000JPY
Revenue from external customers IFRSInterimDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSInterimDuration1332390000000JPY
Intersegment revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000PharmaceuticalsReportableSegmentMember－JPY
Intersegment revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000NutraceuticalsReportableSegmentMember16000000JPY
Intersegment revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000ConsumerProductsReportableSegmentMember15000000JPY
Intersegment revenue IFRSInterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1758000000JPY
Intersegment revenue IFRSInterimDuration_ReportableSegmentsMember1790000000JPY
Intersegment revenue IFRSInterimDuration_ReconcilingItemsMember-1790000000JPY
Intersegment revenue IFRSInterimDuration－JPY
Revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000PharmaceuticalsReportableSegmentMember951614000000JPY
Revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000NutraceuticalsReportableSegmentMember300145000000JPY
Revenue IFRSInterimDuration_jpcrp040300-ssr_E21183-000ConsumerProductsReportableSegmentMember17452000000JPY
Revenue IFRSInterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember64968000000JPY
Revenue IFRSInterimDuration_ReportableSegmentsMember1334181000000JPY
Revenue IFRSInterimDuration_ReconcilingItemsMember-1790000000JPY
Revenue IFRSInterimDuration1332390000000JPY
Operating profit loss IFRSInterimDuration_jpcrp040300-ssr_E21183-000PharmaceuticalsReportableSegmentMember250409000000JPY
Operating profit loss IFRSInterimDuration_jpcrp040300-ssr_E21183-000NutraceuticalsReportableSegmentMember36848000000JPY
Operating profit loss IFRSInterimDuration_jpcrp040300-ssr_E21183-000ConsumerProductsReportableSegmentMember13809000000JPY
Operating profit loss IFRSInterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember6164000000JPY
Operating profit loss IFRSInterimDuration_ReportableSegmentsMember307232000000JPY
Operating profit loss IFRSInterimDuration_ReconcilingItemsMember-28687000000JPY
Operating profit loss IFRSInterimDuration278544000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-07-31
Semi annual accounting period cover pageFilingDateInstant
Original text (Japanese)第19期中（自　2026年１月１日　至　2026年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)大塚ホールディングス株式会社
Company name in english cover pageFilingDateInstantOtsuka Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO　　井上　眞
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区神田司町二丁目９番地（同所は登記上の所在地であり、実際の業務は下記の最寄りの連絡場所で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant03－6717－1410
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)コーポレートアカウンティング部長　小宅　圭子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区港南二丁目16番４号　品川グランドセントラルタワー12階
Telephone number nearest place of contact cover pageFilingDateInstant03－6717－1410
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)コーポレートアカウンティング部長　小宅　圭子
Place for public inspection cover page (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass